drugset

drugset / Trial / NCT03785496

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

NCT03785496 ↗

Phase 2 Unknown 44 enrolled Yonsei University

NaSingle-groupOpen-labelTreatment

Summary

Single arm phase II PDR001( 300mg, IV) will be treated every 3 weeks

Timeline

Start: 2020-02-18
Primary completion: 2022-01
Completion: 2024-01

Publications

Lee DK, Park SR, Kim YH, Lee YG, Shin SJ, Ahn BC, Lee SS, Lim SM, Kim HR, Cho BC, Hong MH. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12). Oncoimmunology. 2024 Jun 24;13(1):2371563. doi: 10.1080/2162402X.2024.2371563. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Spartalizumab	Monoclonal antibody	300 mg	Intravenous

Indications